TCM
AUPH icon

Teza Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Teza Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,910
Closed -$95.8K – 320
2025
Q1 		$95.8K Buy
+11,910
New +$96.5K 0.04% 392
2024
Q4 		– Sell
-28,452
Closed -$209K – 506
2024
Q3 		$209K Buy
+28,452
New +$176K 0.02% 547

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Teza Capital Management's AUPH Position: Q2 2025 in Review

Teza Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 11,910 shares — an estimated $95.8K sold.

Teza Capital Management first reported a position in AUPH in Q3 2024 and held it in 2 quarters. The position peaked at $209K in Q3 2024. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Teza Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 11,910 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $95.8K.
  • Teza Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Teza Capital Management's Aurinia Pharmaceuticals position peaked at $209K in Q3 2024.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.